TORONTO – Vancouver, British Columbia-based Aspect Biosystems Inc. has raised CA$26 million (US$20 million) in series A funding to help develop 3D bioprinter technology that uses the science of microfluidics to create fresh human tissue.
IDbyDNA Inc., a San Francisco-based metagenomics technology company, scooped up $20 million in series B financing in a round led by Artis Ventures. Genesys Capital and others participated in the round. The company plans to use the money to accelerate uptake of its Explify software platform.
Timber Pharmaceuticals LLC, a startup created by New Jersey-based investment and operating firm Tardimed Sciences LLC, said it's poised to make a fresh leap into the public market this year with plans to take over Biopharmx Corp.'s NYSE listing in a new reverse merger deal.
HONG KONG – South Korea’s Genomictree Co. Ltd. has said its U.S. branch, Promis Diagnostics Inc., based in Pasadena, Calif., gained $30.8 million in funds this month. The Daejeon-based company has secured $40.8 million for its U.S. subsidiary since founding it in August 2019.
LONDON – Sequana Medical NV has raised €19 million (US$21 million) in a private placing to fund continuation of the U.S. pivotal trial of its Alfapump in treating ascites due to cirrhosis of the liver and a European trial of the device in heart failure patients who have stopped responding to diuretics.